176 related articles for article (PubMed ID: 26202195)
1. Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease.
Pandolfi F; Frosali S; Petruzziello L; Newton EE; Costamagna G
Mini Rev Med Chem; 2015; 16(3):218-21. PubMed ID: 26202195
[TBL] [Abstract][Full Text] [Related]
2. Involvement of central immunity in uncomplicated diverticular disease.
Cianci R; Iacopini F; Petruzziello L; Cammarota G; Pandolfi F; Costamagna G
Scand J Gastroenterol; 2009; 44(1):108-15. PubMed ID: 18759154
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.
Lopetuso LR; Petito V; Scaldaferri F; Gasbarrini A
Mini Rev Med Chem; 2015; 16(3):179-85. PubMed ID: 26643042
[TBL] [Abstract][Full Text] [Related]
4. Medical Treatment of Diverticular Disease: Antibiotics.
Lué A; Laredo V; Lanas A
J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S57-9. PubMed ID: 27622367
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
6. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.
Stallinger S; Eller N; Högenauer C
Wien Klin Wochenschr; 2014 Jan; 126(1-2):9-14. PubMed ID: 24240607
[TBL] [Abstract][Full Text] [Related]
7. Non-absorbable antibiotics in the treatment of diverticular disease of the colon.
Papi C; Camarri E
Ital J Gastroenterol; 1992; 24(9 Suppl 2):19-22. PubMed ID: 1336684
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
Papi C; Ciaco A; Koch M; Capurso L
Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
[TBL] [Abstract][Full Text] [Related]
9. Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin.
Cianci R; Frosali S; Pagliari D; Cesaro P; Petruzziello L; Casciano F; Landolfi R; Costamagna G; Pandolfi F
J Immunol Res; 2014; 2014():696812. PubMed ID: 25133198
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine for diverticular disease of the colon--a new role for an old drug.
Tursi A
Expert Opin Pharmacother; 2005 Jan; 6(1):69-74. PubMed ID: 15709884
[TBL] [Abstract][Full Text] [Related]
11. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
12. [The rifaximin therapy and prophylaxis of episodes of acute diverticulitis].
Iosca N; Ferrieri A
Recenti Prog Med; 1993 Jan; 84(1):49-53. PubMed ID: 8430251
[TBL] [Abstract][Full Text] [Related]
13. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
Tursi A; Papa A; Danese S
Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
[TBL] [Abstract][Full Text] [Related]
14. [Chronic diverticular diseases. Rifaximin reduces symptoms and complications].
MMW Fortschr Med; 2010 May; 152(21):98-9. PubMed ID: 20608137
[No Abstract] [Full Text] [Related]
15. The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis.
Banasiewicz T; Francuzik W; Bobkiewicz A; Krokowicz Ł; Borejsza-Wysocki M; Paszkowski J; Studniarek A; Krokowicz P; Grochowalski M; Szczepkowski M; Lorenc Z
Pol Przegl Chir; 2017 Feb; 89(1):22-31. PubMed ID: 28522790
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon.
Giaccari S; Tronci S; Falconieri M; Ferrieri A
Riv Eur Sci Med Farmacol; 1993; 15(1):29-34. PubMed ID: 8159832
[TBL] [Abstract][Full Text] [Related]
17. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
Cuomo R; Barbara G; Annibale B
Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
[TBL] [Abstract][Full Text] [Related]
19. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study.
Tursi A; Elisei W; Brandimarte G; Giorgetti GM; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E
Neurogastroenterol Motil; 2012 Sep; 24(9):836-e396. PubMed ID: 22680042
[TBL] [Abstract][Full Text] [Related]
20. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
